Provided by Tiger Fintech (Singapore) Pte. Ltd.

CNS Pharmaceuticals, Inc.

0.8989
+0.07899.62%
Volume:182.19K
Turnover:157.09K
Market Cap:2.65M
PE:-0.02
High:0.8999
Open:0.8548
Low:0.7950
Close:0.8200
Loading ...

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year

TipRanks
·
02 Apr

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

ACCESS Newswire
·
01 Apr

CNS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

CNS Pharmaceuticals Inc expected to post a loss of $9.66 a share - Earnings Preview

Reuters
·
28 Mar

CNS Pharmaceuticals announces primary analysis of berubicin in GBM

TIPRANKS
·
26 Mar

CNS Pharmaceuticals Cut to Hold From Buy by Maxim Group

Dow Jones
·
26 Mar

CNS Pharma Shares Sink After Berubicin Trial for Brain Cancer Misses Survival Endpoint

Dow Jones
·
25 Mar

CNS Pharmaceuticals - Berubicin Showed Clinically Relevant Outcomes Comparable to Lomustine Across Multiple Endpoints

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals Inc: Berubicin Did Not Show a Statistically Significant Difference in Overall Survival, the Primary Endpoint

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals Inc -Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals-Continues Development of Novel Taxane, TPI 287, With Published Clinical Efficacy Data in Glioblastoma Multiforme

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals Shares Halted for News Pending Premarket

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals Inc - Pursuant to Sales Agreement, Increases Sales Price of Shares to $43.5 Mln

THOMSON REUTERS
·
21 Mar

CNS Pharmaceuticals reports cash position of $14M as of February 26

TIPRANKS
·
26 Feb

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

ACCESS Newswire
·
26 Feb

S&P 500 Edges Higher; Analog Devices Earnings Top Views

Benzinga
·
20 Feb

CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down

MT Newswires Live
·
19 Feb

CNS Pharmaceuticals announces 1-for-50 reverse stock split

TIPRANKS
·
19 Feb

CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit

TIPRANKS
·
18 Feb

CNS Pharmaceuticals Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $4

THOMSON REUTERS
·
24 Jan